Last reviewed · How we verify

South China Children Cancer Group - Relapsed-Acute Lymphoblastic Leukemia 2022 Protocol (SCCCG-R-ALL)

NCT05682131 PHASE4 RECRUITING

In recent years, the prognosis of pediatric relapsed ALL patients has improved, but the 5-year OS of patients with first recurrence is still less than 50%. A number of in vitro studies have shown that arsenic trioxide (ATO) can selectively inhibit the growth and induce apoptosis in a variety of leukemia cell lines, suggesting that ATO as a synergist combined with other common chemotherapy drugs may provide a new target for the treatment of relapsed ALL. Realgar Indigo naturalis formula is a compound traditional Chinese medicine preparation developed in China. The main component of realgar is arsenic tetrasulfide (As4S4), which can produce similar pharmacological effects to ATO. Based on the R3 protocol, this study plans to perform a double-blind randomized controlled trial, and to randomly combine compound Huangdai tablets with compound Huangdai tablets in the treatment of intermediate and high risk ALL children, in order to improve the MRD negative rate after induction therapy in this group of children, which may provide a new method for the clinical treatment of relapsed ALL.

Details

Lead sponsorSun Yat-Sen Memorial Hospital of Sun Yat-Sen University
PhasePHASE4
StatusRECRUITING
Enrolment210
Start dateTue Sep 27 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
CompletionFri Sep 27 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Interventions

Countries

China